Acute and Hyperacute Humoral Rejection in Kidney Allograft Recipients Treated with Anti-Human Thymocyte Antibodies

Colovai, Adriana I.; Vasilescu, Elena R.; Foca-Rodi, Aurica; Kim‐Schulze, Seunghee; Hussaini, Najeeb S.; D’Agati, Vivette D.; Markowitz, Glen S.; Wang, Chuan; Cohen, David J.; Hardy, Mark A.; Suciu‐Foca, Nicole

doi:10.1016/j.humimm.2005.01.009

Cited by 30 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the targets of ATG, such as the HLA Ag, may also be expressed on other cell types, and may become targets of ATG cytotoxicity. It has already been suspected in a few kidney and heart recipients that ATG treatment can lead to C4d deposition in the graft, and possibly to graft rejection [23,24]. In our patients, the use of ATG containing anti-HLA-A3 Ab was never associated with severe reactions, graft dysfunction, or rejection.…”

Section: Discussionsupporting

confidence: 44%

Misleading de novo detection of serum anti–HLA-A3 antibodies in kidney recipients having received ATG before transplantation

et al. 2010

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 44%

Misleading de novo detection of serum anti–HLA-A3 antibodies in kidney recipients having received ATG before transplantation

et al. 2010

View full text Add to dashboard Cite

“…151 Prophylactic ATG (RATG and equine ATG) has been reported in 1 study to induce acute and hyperacute AMR in nonsensitized patients with renal allografts. 152 Although there have been successful cases in which AMR has been treated successfully with ATG in combination with other immunosuppressive therapy, this class of drugs requires testing as part of a randomized trial in AMR. 108,143,[153][154][155][156] …”

Section: Anti-lymphocyte Globulinsmentioning

confidence: 99%

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Colvin¹,

Cook²,

Chang³

et al. 2015

Circulation

285

251

View full text Add to dashboard Cite

“…These technologies have gained wide acceptance for tissue typing and immunology (18). Their use for infectious disease control is expanding, even in low-resource countries (19).…”

mentioning

confidence: 99%

Tuberculosis-Spoligo-Rifampin-Isoniazid Typing: an All-in-One Assay Technique for Surveillance and Control of Multidrug-Resistant Tuberculosis on Luminex Devices

et al. 2013

View full text Add to dashboard Cite

e As a follow-up of the "spoligoriftyping" development, we present here an extension of this technique which includes the detection of isoniazid resistance-associated mutations in a new 59-plex assay, i.e., tuberculosis-spoligo-rifampin-isoniazid typing (TB-SPRINT), running on microbead-based multiplexed systems. This assay improves the synergy between clinical microbiology and epidemiology by providing (i) mutation-based prediction of drug resistance profiles for patient treatment and (ii) genotyping data for tuberculosis (TB) surveillance. This third-generation microbead-based high-throughput assay for TB runs on the Luminex 200 system and on the recently launched MagPix system (Luminex, Austin, TX). Spoligotyping patterns obtained by the TB-SPRINT method were 100% (n ‫؍‬ 85 isolates; 3,655/3,655 spoligotype data points) concordant with those obtained by microbead-based and membrane-based spoligotyping. Genetic drug susceptibility typing provided by the TB-SPRINT method was 100% concordant with resistance locus sequencing (n ‫؍‬ 162 for rpoB gene sequencing and n ‫؍‬ 76 for katG and inhA sequencing). Considering phenotypic drug susceptibility testing (DST) as the reference method, the sensitivity and specificity of TB-SPRINT regarding Mycobacterium tuberculosis complex (n ‫؍‬ 162 isolates) rifampin resistance were both 100%, and those for isoniazid resistance were 90.4% (95% confidence interval, 85 to 95%) and 100%, respectively. Used routinely in national TB reference and specialized laboratories, the TB-SPRINT assay should simultaneously improve personalized medicine and epidemiological surveillance of multidrug-resistant (MDR) TB. This assay is expected to play an emerging role in public health in countries with heavy burdens of MDR TB and/or HIV/TB coinfection. Application of this assay directly to biological samples, as well as development for extensively drug-resistant (XDR) TB detection by inclusion of second-line antituberculosis drug-associated mutations, is under development. With bioinformatical methods and data mining to reduce the number of targets to the most informative ones, locally adapted formats of this technique can easily be developed everywhere.

show abstract

Acute and Hyperacute Humoral Rejection in Kidney Allograft Recipients Treated with Anti-Human Thymocyte Antibodies

Cited by 30 publications

References 41 publications

Misleading de novo detection of serum anti–HLA-A3 antibodies in kidney recipients having received ATG before transplantation

Misleading de novo detection of serum anti–HLA-A3 antibodies in kidney recipients having received ATG before transplantation

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Tuberculosis-Spoligo-Rifampin-Isoniazid Typing: an All-in-One Assay Technique for Surveillance and Control of Multidrug-Resistant Tuberculosis on Luminex Devices

Contact Info

Product

Resources

About